ORSERDUTM (ELACESTRANT)

Publications

Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors:
Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups

VIEW NOW

  Journal of Clinical Oncology (2022): Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

VIEW NOW

Journal of Clinical Oncology (2021): Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

VIEW NOW

Presentations

Nothing found.

ELZONRIS® (TAGRAXOFUSP)

Publications

Journal of Clinical Oncology (2022): Long-Term Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

VIEW NOW

  New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

VIEW NOW

Presentations

Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth And Osteolytic Bone Disease. ASCO 2014.

Abstract | Poster

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2013.

Abstract | Poster

Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model. ASH 2013.

Abstract | Poster

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia. ASH 2013.

Abstract | Poster

SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASH 2013.

Abstract | Poster

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies. ASCO 2013.

Abstract | Poster

SL-801

Nothing found.

SL-701

Nothing found.